Physician profile
Peter Garcia
NPI 1437273687
$1,053.72
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.78 · 2020: $54.14 · 2021: $106 · 2022: $165 · 2023: $247 · 2024: $143 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.67 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.78 | 2022-2025 | Caplyta |
| Abbvie INC. | $165.29 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $154.96 | 2019-2024 | Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $107.43 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $100.51 | 2021-2025 | Invega Sustenna |
| Alkermes, INC. | $88.39 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $68.76 | 2023-2024 | Uzedy, Austedo |
| Almatica Pharma LLC | $51.85 | 2022-2025 | Loreev Xr |
| Allergan, INC. | $29.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.40 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $24.27 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $23.71 | 2025 | Fanapt |
| Tms Neurohealth Centers INC. | $22.63 | 2025 | Tms Neurohealth Centers INC. |
| Lundbeck LLC | $19.75 | 2023 | Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.